Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.

Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P. · 2022

Read Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. by Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9671806.txt.

Introduction

Gogishvili and co-authors report the EMPOWER-Lung 3 phase 3 trial of cemiplimab plus chemotherapy in lung cancer. Cemiplimab alone had already beaten chemotherapy in high PD-L1 cases. This trial tested the pair as first treatment for advanced disease. It took patients no matter their PD-L1 level or tumor type.

The double-blind trial randomized 466 patients in a two to one split. The drug arm had 312 patients and the placebo arm had 154. All got platinum-doublet chemotherapy with their assigned drug. Median overall survival was 21.9 months on the pair. It was 13.0 months on chemotherapy with placebo. The trial stopped early once preset survival marks were met. Severe adverse events came more often in the drug arm. The authors say the pair works for both squamous and non-squamous disease.

Catalog record

CREATORGogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9671806

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial By Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner Published in: Nature Medicine DOI: 10.1038/s41591-022-01977-y ABSTRACT Abstract First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC) and PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 (NCT03409614), a double-blind, placebo-controlled, phase 3 study, examined cemiplimab plus platinum-doublet chemotherapy as first-line treatment for aNSCLC, irrespective of PD-L1 expression or histology. In this study, 466 patients with stage III/IV aNSCLC without EGFR, ALK or ROS1 genomic tumor aberrations were randomized (2:1) to receive cemiplimab 350 mg (n = 312) or placebo (n = 154) every 3 weeks for up to 108 weeks in combination with four cycles of platinum-doublet chemotherapy (followed by pemetrexed maintenance as indicated). In total, 57.1% (266/466 patients) had non-squamous NSCLC, and 85.2% (397/466 patients) had stage IV disease. The primary endpoint was OS. The trial was stopped early per recommendation of the independent data monitoring committee, based on meeting preset OS efficacy criteria: median OS was 21.9 months (95% confidence interval (CI), 15.5–not evaluable) with cemiplimab plus chemotherapy versus 13.0 months (95% CI, 11.9–16.1) with placebo plus chemotherapy (hazard ratio (HR) = 0.71; 95% CI, 0.53–0.93; P = 0.014). Grade ≥3 adverse events occurred with cemiplimab plus chemotherapy (43.6%, 136/312 patients) and placebo plus chemotherapy (31.4%, 48/153 patients). Cemiplimab is only the second anti-PD-1/PD-L1 agent to show efficacy in aNSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies. Subject terms: Non-small-cell lung cancer, Cancer immunotherapy MAIN PD-1 and PD-L1 inhibitors are the mainstay of systemic treatment for aNSCLC in patients without therapeutically actionable tumor genomic aberrations, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations or ROS proto-oncogene 1 (ROS1) fusions1–3. Pembrolizumab and atezolizumab (anti–PD-L1) are both approved as first-line therapies in combination with platinum-based chemotherapy and other therapies for certain patient populations with metastatic NSCLC, although atezolizumab approval with platinum-doublet chemotherapy is limited to non-squamous histology2,4,5. Combinations of checkpoint inhibitors—ipilimumab (anti–cytotoxic T-lymphocyte-associated protein 4) plus nivolumab (anti–PD-1) with or without chemotherapy—are also approved for patients with aNSCLC irrespective of histology, but the clinical utility of these agents compared to single-agent checkpoint treatments alone or in combination with chemotherapy is unclear6,7. After demonstration of superior survival benefit for cemiplimab as monotherapy versus chemotherapy in EMPOWER-Lung 1 (ref. 8), cemiplimab was approved in the United States and the European Union as first-line treatment for patients with aNSCLC and PD-L1 ≥ 50% and with no EGFR, anaplastic ALK or ROS1 genomic aberrations, and is a preferred treatment for these patients by National Comprehensive Cancer Network (NCCN) guidelines1,8–11. In EMPOWER-Lung 3, we examined first-line cemiplimab in combination with investigator’s choice of platinum-doublet chemotherapy in patients with aNSCLC (metastatic or unresectable locally advanced disease not suitable for definitive chemoradiation), with either squamous or non-squamous histology and any level of PD-L1 expression. RESULTS Patient characteristics In total, 904 patients were screened for enrollment at 74 sites in ten countries (Supplementary Table 1). Between 17 June 2019 and 30 September 2020, 466 patients were enrolled and randomly assigned 2:1 to cemiplimab plus chemotherapy (n = 312) and placebo plus chemotherapy (n = 154) treatment arms (Fig. 1). All patients who received cemiplimab plus chemotherapy and 153 patients (99.4%) in the placebo plus chemotherapy arm received at least one dose of study treatment. Baseline characteristics were generally well balanced between both arms; 42.9% (n = 200) of patients had squamous histology, 84.3% (n = 393) of patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1, and 14.8% (n = 69) of patients had locally advanced disease (Table 1). [Figure: CONSORT diagram of EMPOWER-Lung 3 part two.All randomized patients were included in the efficacy analyses, and all patients who received treatment were included in the safety analyses.] [Table: Baseline characteristics of the intention-to-treat patient population] The trial was stopped early per recommendation of the independent data monitoring committee (IDMC), based on meeting preset criteria for OS efficacy (Methods). At the time of data cutoff (14 June 2021), 108 patients in the cemiplimab plus chemotherapy arm and 15 patients in the placebo plus chemotherapy arm remained on treatment. In the cemiplimab plus chemotherapy arm, 204 (65.4%) patients discontinued treatment, primarily due to progressive disease. In the placebo plus chemotherapy arm, 138 (89.6%) patients discontinued treatment, primarily due to progressive disease. The median duration of follow-up was 16.3 months (interquartile range (IQR), 13.9–19.1) in the cemiplimab plus chemotherapy arm and 16.7 months (IQR, 14.2–19.0) in the placebo plus chemotherapy arm. Treatment exposures are summarized in Supplementary Table 2. OS With 214 deaths, the primary endpoint, median OS with cemiplimab plus chemotherapy, was 21.9 months (95% CI, 15.5–not evaluable (NE)) versus 13.0 months (95% CI, 11.9–16.1) with placebo plus chemotherapy (HR = 0.71; 95% CI, 0.53–0.93; P = 0.014; Fig. 2a). In the cemiplimab plus chemotherapy arm, the secondary endpoint of estimated proportion of patients who were alive at 12 months was 65.7% (95% CI, 59.9–70.9) versus 56.1% (95% CI, 47.5–63.8) in the placebo plus chemotherapy arm. [Figure: Survival data for the cemiplimab plus chemotherapy and placebo plus chemotherapy arms.a, Kaplan–Meier OS curves of all patients. b, Forest plots of OS by subgroups. c, Kaplan–Meier PFS curves of all patients. d, Forest plots of PFS by subgroups. Median OS and PFS and corresponding two-sided 95% CIs were estimated by the Kaplan–Meier method. HRs and corresponding two-sided 95% CIs for OS and PFS were calculated using a stratified Cox proportional hazard model with Efron’s method of tie handling. Cemi, cemiplimab; chemo, chemotherapy; met, metastasis; PBO, placebo.] Although the study was not powered to examine efficacy within predefined subgroups, numeric improvements in OS were seen in both the squamous and non-squamous histology subgroups. In the squamous histology subgroup, median OS was 21.9 months (95% CI, 15.6–NE) with cemiplimab plus chemotherapy versus 13.8 months (95% CI, 9.3–18.0) in the placebo arm (HR = 0.56; 95% CI, 0.37–0.84). In the non-squamous histology subgroup, median OS was 15.8 months (95% CI, 13.7–NE) with cemiplimab arm versus 13.0 months (95% CI, 10.0–NE) with placebo plus chemotherapy (HR = 0.79; 95% CI, 0.54–1.14). Of note, due to the capping applied to the enrollment of patients with squamous histology, follow-up was shorter in the non-squamous subset (14.7 months; IQR, 12.5–17.9) versus the squamous subset (18.2 months; IQR, 15.9–20.2). In other predefined subgroups, OS estimates consistently favored cemiplimab plus chemotherapy except in women, never-smokers and patients with PD-L1 < 1% (Fig. 2b). Of note, there was overlap among these three subgroups, which were generally small, and the discrepancies noted in OS were not observed in the other efficacy endpoints of PFS and objective response rate (ORR), which reflect an earlier treatment effect. PFS With 326 events of progressive disease or death, the key secondary endpoint of median PFS with cemiplimab plus chemotherapy was 8.2 months (95% CI, 6.4–9.3) versus 5.0 months (95% CI, 4.3–6.2) for the placebo plus chemotherapy arm

Read the complete text